Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
NeoGenomics Total Current Liabilities Related Terms
NeoGenomics Total Current Liabilities Historical Data
* Premium members only.
The historical data trend for NeoGenomics's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of MXN1,848 Mil mean?
NeoGenomics (MEX:NEO) has a Total Current Liabilities of MXN1,848 Mil as of Jun. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for NeoGenomics and its competitors.
Is NeoGenomics' Total Current Liabilities too high?
NeoGenomics' current Total Current Liabilities is MXN1,848 Mil. Overall, NeoGenomics has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Total Current Liabilities compare to WGS and CDNA?
NeoGenomics' Total Current Liabilities of MXN1,848 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Diagnostics & Research company?
A good Total Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for NeoGenomics and its competitors. NeoGenomics's current Total Current Liabilities is MXN1,848 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
NeoGenomics (MEX:NEO) has a current Total Current Liabilities of MXN1,848 Mil. The stock's GF Value™ is MXN177.40, compared to a current price of MXN176.40 — trading 0.6% below its estimated fair value. The current Total Current Liabilities is MXN1,848 Mil. NeoGenomics' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Total Current Liabilities is MXN1,848 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeoGenomics (MEX:NEO) Overvalued in 2026?
Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued.
The current stock price of MXN176.40 is trading 0.6% below its estimated GF Value™ of MXN177.40.
Key valuation signals for MEX:NEO:
Total Current Liabilities: MXN1,848 Mil
GF Value™: MXN177.40 vs. price of MXN176.40 (0.6% below fair value)
No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
74GF Score
Get the complete analysis for MEX:NEO
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NEO has been successfully added to your 
